Measured Wealth Private Client Group’s Lockheed Martin LMT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$154K Sell
302
-202
-40% -$109K 0.04% 223
2026
Q1
$305K Buy
504
+333
+195% +$205K 0.08% 140
2025
Q4
$82.7K Hold
171
– – 0.02% 258
2025
Q3
$85.4K Buy
+171
New +$77.6K 0.02% 253
2021
Q1
– Sell
-699
Closed -$248K – 161
2020
Q4
$248K Sell
699
-195
-22% -$71.7K 0.1% 119
2020
Q3
$343K Sell
894
-173
-16% -$66K 0.17% 79
2020
Q2
$389K Buy
1,067
+448
+72% +$169K 0.23% 58
2020
Q1
$210K Buy
+619
New +$243K 0.16% 82
2019
Q4
– Sell
-672
Closed -$262K – 125
2019
Q3
$262K Sell
672
-150
-18% -$56.4K 0.17% 92
2019
Q2
$299K Buy
+822
New +$275K 0.17% 130
2018
Q4
– Sell
-162
Closed -$56K – 434
2018
Q3
$56K Buy
+162
New +$52.3K 0.03% 327

Other funds holding LMT

Measured Wealth Private Client Group's LMT Position: Q2 2026 in Review

Measured Wealth Private Client Group reduced its Lockheed Martin (LMT) stake by 40% in Q2 2026, selling an estimated $109K and leaving 302 shares worth $154K. The position accounts for 0.04% of the portfolio, ranked #223.

Measured Wealth Private Client Group first reported a position in LMT in Q3 2018 and has held it in 11 quarters since. The position peaked at $389K in Q2 2020. 2,789 funds tracked by Wall St. Rank hold LMT as of Q2 2026.

  • Measured Wealth Private Client Group held 302 shares of Lockheed Martin worth $154K as of Q2 2026.
  • Measured Wealth Private Client Group sold 202 Lockheed Martin shares in Q2 2026, an estimated $109K.
  • Lockheed Martin made up 0.04% of Measured Wealth Private Client Group's portfolio in Q2 2026, its #223 holding.
  • Measured Wealth Private Client Group first reported a position in Lockheed Martin in Q3 2018 and has held it in 11 quarters since.
  • Measured Wealth Private Client Group's Lockheed Martin position peaked at $389K in Q2 2020.
  • 2,789 funds tracked by Wall St. Rank held Lockheed Martin as of Q2 2026.

Based on Measured Wealth Private Client Group's 13F filing for Q2 2026, filed 10 Aug 2026.